— The interest in Beyfortus is enormous. Unfortunately, this has led to a global demand that exceeds the availability of doses. In this difficult situation, Sanofi has had to prioritize the countries that have already signed agreements and ensure that their needs for doses are covered, says Sanofi’s Sweden CEO Per Öhlén to the newspaper.
Beyfortus, with the active substance nirsevimab, is a preventive treatment against the virus that causes the respiratory tract infection bronchiolitis in infants.
Bronchiolitis is an infection of the lower respiratory tract in children aged 0-2 years that is normally mild, but in some cases can make infants seriously ill. The RS virus, which is common during the winter months, causes 70-90 percent of cases of bronchiolitis.
In November last year, the European Commission approved the drug.